NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Synthesize Bio

Synthesize Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.synthesize.bio/

Last Round

Seed

Sep 17, 2025

Total Funding Raised

$10M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Synthesize Bio is a biotechnology company that develops a generative genomics platform using multi-modal deep learning models to simulate biological processes and accelerate drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Foundation

Keywords

generative genomicsfoundation modelfrontier ai labsynthetic biologyprotein engineeringdrug discoverycomputational biologyrna-seqsynthetic datasetsai drug discoverybio-aiprotein designapi platformbiotech softwareclinical trial design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synthesize Bio Comparables

Compare Synthesize Bio with similar companies based on industry and business-model similarity.

Synthesize Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EvolutionaryScale
89%
Chai Discovery
83%
Cassidy Bio
81%

Synthesize Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 17, 2025

Key People

Founding team and executive leadership

Jeff Leek

Co-CEO Co-Founder

Founding Team

Alice Walsh

Chief Operating Officer

Executive Team

Synthesize Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 27, 2026

    Grew 24% QoQ from 17 to 21 employees.

Synthesize Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Synthesize Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synthesize Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range21
Year Founded2023
Last FundingSep 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.